Perimeter Medical Imaging AI Set to Trade on OTCQX Starting February 27, 2025
Perimeter Medical Imaging AI, Inc. is gearing up for a significant milestone in its operations. As of February 27, 2025, the company will begin trading on the OTCQX® Best Market under the ticker symbol "PYNKF." This marks a pivotal transition from the Pink® market, a move that is seen as a strategic enhancement to the firm’s presence in the U.S. markets, especially given the substantial interest from American shareholders.
Adrian Mendes, the Chief Executive Officer of Perimeter, highlighted the importance of this transition, stating, "Many of our shareholders are based in the United States and the U.S. is the primary target market for our current S-Series OCT system, as well as our upcoming AI-enabled B-Series product." The shift to the OTCQX is expected to not only increase market visibility but also boost the company’s appeal among potential investors.
In recent developments, Perimeter reported encouraging topline results from a clinical study essential for its U.S. FDA premarket approval application for the B-Series system, which incorporates ImgAssist AI 2.0 technology. The clinical trial aimed at demonstrating the system's efficacy in breast-conserving surgeries, achieving a statistically significant reduction (p-value = 0.0050) in residual cancer presence during operations. This finding supports the notion that the B-Series system could potentially reduce the need for reoperations by assisting surgeons in obtaining clear margins.
With the B-Series OCT system still under investigational use and not available for commercial sale within the U.S., the company's commitment to innovation in cancer surgery continues unabated. Perimeter's existing S-Series OCT system, already cleared by the FDA, is currently operational in the U.S., allowing for real-time visualizations of excised tissue at the cellular level.
Moreover, the development of the B-Series was supported by a notable grant amounting to approximately USD 7.4 million from the Cancer Prevention and Research Institute of Texas, highlighting the company’s drive to innovate in areas with high unmet medical needs.
Perimeter Medical Imaging AI strives to revolutionize surgical procedures with advanced imaging technologies designed for optimal patient outcomes, encapsulated in their mission to form a cutting-edge solution to challenges faced in cancer surgery.
As the company prepares for this trade upgrade, it also maintains its listing on the TSX Venture Exchange under the existing symbol "PINK." This dual presence is designed to cater to both U.S. and Canadian investors, reflecting Perimeter's commitment to expanding its shareholder base in multiple jurisdictions.
This strategic transition to OTCQX could very well enhance transparency and improve regular communications with investors, alongside potentially delivering better trading liquidity for its stock. Overall, this move underscores Perimeter Medical Imaging AI’s commitment to playing a transformative role in the realm of medical imaging and surgery, bolstered by exciting advancements in technology that promise to improve patient care and outcomes.
Adrian Mendes, the Chief Executive Officer of Perimeter, highlighted the importance of this transition, stating, "Many of our shareholders are based in the United States and the U.S. is the primary target market for our current S-Series OCT system, as well as our upcoming AI-enabled B-Series product." The shift to the OTCQX is expected to not only increase market visibility but also boost the company’s appeal among potential investors.
In recent developments, Perimeter reported encouraging topline results from a clinical study essential for its U.S. FDA premarket approval application for the B-Series system, which incorporates ImgAssist AI 2.0 technology. The clinical trial aimed at demonstrating the system's efficacy in breast-conserving surgeries, achieving a statistically significant reduction (p-value = 0.0050) in residual cancer presence during operations. This finding supports the notion that the B-Series system could potentially reduce the need for reoperations by assisting surgeons in obtaining clear margins.
With the B-Series OCT system still under investigational use and not available for commercial sale within the U.S., the company's commitment to innovation in cancer surgery continues unabated. Perimeter's existing S-Series OCT system, already cleared by the FDA, is currently operational in the U.S., allowing for real-time visualizations of excised tissue at the cellular level.
Moreover, the development of the B-Series was supported by a notable grant amounting to approximately USD 7.4 million from the Cancer Prevention and Research Institute of Texas, highlighting the company’s drive to innovate in areas with high unmet medical needs.
Perimeter Medical Imaging AI strives to revolutionize surgical procedures with advanced imaging technologies designed for optimal patient outcomes, encapsulated in their mission to form a cutting-edge solution to challenges faced in cancer surgery.
As the company prepares for this trade upgrade, it also maintains its listing on the TSX Venture Exchange under the existing symbol "PINK." This dual presence is designed to cater to both U.S. and Canadian investors, reflecting Perimeter's commitment to expanding its shareholder base in multiple jurisdictions.
This strategic transition to OTCQX could very well enhance transparency and improve regular communications with investors, alongside potentially delivering better trading liquidity for its stock. Overall, this move underscores Perimeter Medical Imaging AI’s commitment to playing a transformative role in the realm of medical imaging and surgery, bolstered by exciting advancements in technology that promise to improve patient care and outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.